Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have been assigned a consensus rating of “Buy” from the ten ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $29.86.

KURA has been the topic of several analyst reports. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Stifel Nicolaus lowered shares of Kura Oncology from a “buy” rating to a “hold” rating and cut their target price for the company from $26.00 to $19.00 in a report on Monday, October 14th. HC Wainwright increased their price target on shares of Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, November 21st. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. Finally, UBS Group assumed coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 target price on the stock.

Kura Oncology Price Performance

NASDAQ:KURA opened at $8.73 on Monday. The firm’s fifty day moving average is $12.48 and its two-hundred day moving average is $17.27. The firm has a market cap of $678.88 million, a price-to-earnings ratio of -3.70 and a beta of 0.81. Kura Oncology has a one year low of $8.42 and a one year high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Institutional Investors Weigh In On Kura Oncology

Several large investors have recently bought and sold shares of the company. nVerses Capital LLC acquired a new stake in shares of Kura Oncology in the third quarter worth approximately $25,000. Point72 DIFC Ltd purchased a new position in Kura Oncology in the 3rd quarter valued at $146,000. Quarry LP acquired a new stake in Kura Oncology during the 2nd quarter worth $196,000. Erste Asset Management GmbH purchased a new stake in shares of Kura Oncology during the third quarter worth $215,000. Finally, Bellevue Group AG raised its position in shares of Kura Oncology by 36.0% in the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after buying an additional 3,600 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.